1. Home
  2. OSS vs ARMP Comparison

OSS vs ARMP Comparison

Compare OSS & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OSS

One Stop Systems Inc.

HOLD

Current Price

$5.86

Market Cap

208.0M

Sector

Technology

ML Signal

HOLD

Logo Armata Pharmaceuticals Inc.

ARMP

Armata Pharmaceuticals Inc.

HOLD

Current Price

$3.25

Market Cap

199.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSS
ARMP
Founded
1998
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
208.0M
199.7M
IPO Year
2017
1996

Fundamental Metrics

Financial Performance
Metric
OSS
ARMP
Price
$5.86
$3.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
★ $19.00
$17.50
AVG Volume (30 Days)
★ 795.1K
113.6K
Earning Date
11-04-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 133.85
N/A
EPS
★ N/A
N/A
Revenue
★ $37,027,382.00
N/A
Revenue This Year
$26.62
N/A
Revenue Next Year
$23.21
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 34.46
N/A
52 Week Low
$4.17
$2.75
52 Week High
$20.88
$14.98

Technical Indicators

Market Signals
Indicator
OSS
ARMP
Relative Strength Index (RSI) 20.07 40.49
Support Level N/A N/A
Resistance Level $14.36 $4.07
Average True Range (ATR) 0.44 0.33
MACD -0.15 -0.01
Stochastic Oscillator 3.01 42.64

Price Performance

Historical Comparison
OSS
ARMP

About OSS One Stop Systems Inc.

One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.

Share on Social Networks: